APA (7th ed.) Citation

Seban, R., Mezquita, L., Berenbaum, A., Dercle, L., Botticella, A., Le Pechoux, C., . . . Besse, B. (2020). Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine & Molecular Imaging, 47(5), 1147. https://doi.org/10.1007/s00259-019-04615-x

Chicago Style (17th ed.) Citation

Seban, Romain-David, et al. "Baseline Metabolic Tumor Burden on FDG PET/CT Scans Predicts Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors." European Journal of Nuclear Medicine & Molecular Imaging 47, no. 5 (2020): 1147. https://doi.org/10.1007/s00259-019-04615-x.

MLA (9th ed.) Citation

Seban, Romain-David, et al. "Baseline Metabolic Tumor Burden on FDG PET/CT Scans Predicts Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors." European Journal of Nuclear Medicine & Molecular Imaging, vol. 47, no. 5, 2020, p. 1147, https://doi.org/10.1007/s00259-019-04615-x.